{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:55:25Z","timestamp":1790013325721,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Almirall"},{"name":"Biofrontera"},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Meda"},{"name":"Schulze & B\u00f6hm GmbH"},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jaad.2019.05.063","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T01:00:07Z","timestamp":1559091607000},"page":"336-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["A randomized phase 3b\/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea"],"prefix":"10.1016","volume":"82","author":[{"given":"Martin","family":"Schaller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Kem\u00e9ny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanka","family":"Havlickova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Mark","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Ambroziak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Lynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Remenyik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Del Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Weglowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Chavda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Kerrouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dirschka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jaad.2019.05.063_bib1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2340\/00015555-2335","article-title":"Facial erythema of rosacea - aetiology, different pathophysiologies and treatment options","volume":"96","author":"Steinhoff","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"10.1016\/j.jaad.2019.05.063_bib2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/exd.13143","article-title":"Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics","volume":"26","author":"Holmes","year":"2017","journal-title":"Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.05.063_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bjd.15173","article-title":"Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel","volume":"176","author":"Schaller","year":"2017","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2019.05.063_bib4","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1468-3083.2009.03167.x","article-title":"Current topical and systemic approaches to treatment of rosacea","volume":"23","author":"Korting","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2019.05.063_bib5","first-page":"CD003262","article-title":"Interventions for rosacea","volume":"4","author":"van Zuuren","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.jaad.2019.05.063_bib6","first-page":"838","article-title":"Optimal management of papulopustular rosacea: rationale for combination therapy","volume":"11","author":"Bhatia","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2019.05.063_bib7","first-page":"909","article-title":"Treatment of rosacea with concomitant use of topical ivermectin 1% cream and brimonidine 0.33% gel: a randomized, vehicle-controlled study","volume":"16","author":"Gold","year":"2017","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.05.063_bib8","first-page":"641","article-title":"Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, USP monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea","volume":"6","author":"Fowler","year":"2007","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.05.063_bib9","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.13408","article-title":"Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial","volume":"172","author":"Taieb","year":"2015","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2019.05.063_bib10","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/jdv.13537","article-title":"Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study","volume":"30","author":"Taieb","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2019.05.063_bib11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s13555-016-0133-6","article-title":"Superior efficacy with ivermectin 1% cream compared to metronidazole 0.75% cream contributes to a better quality of life in patients with severe papulopustular rosacea: a subanalysis of the randomized, investigator-blinded ATTRACT study","volume":"6","author":"Schaller","year":"2016","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"9","key":"10.1016\/j.jaad.2019.05.063_bib12","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s12325-016-0380-z","article-title":"Topical ivermectin 10 mg\/g and oral doxycycline 40 mg modified-release: current evidence on the complementary use of anti-inflammatory rosacea treatments","volume":"33","author":"Steinhoff","year":"2016","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.jaad.2019.05.063_bib13","first-page":"316","article-title":"Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies","volume":"13","author":"Stein Gold","year":"2014","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.05.063_bib14","first-page":"703","article-title":"Effectiveness and safety of modified-release doxycycline capsules once daily for papulopustular rosacea monotherapy results from a large community-based trial in subgroups based on gender","volume":"11","author":"Del Rosso","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.05.063_bib15","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaad.2016.01.023","article-title":"Improved clinical outcome and biomarkers in adults with papulopustular rosacea treated with doxycycline modified-release capsules in a randomized trial","volume":"74","author":"di Nardo","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.063_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.jaad.2019.05.063_bib17","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/09546634.2017.1343435","article-title":"Defining treatment success in rosacea as 'clear' may provide multiple patient benefits: results of a pooled analysis","volume":"28","author":"Webster","year":"2017","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.jaad.2019.05.063_bib19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jaad.2017.03.040","article-title":"Role of Demodex mite infestation in rosacea: a systematic review and meta-analysis","volume":"77","author":"Chang","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2019.05.063_bib20","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1111\/jdv.14437","article-title":"Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea","volume":"31","author":"Schaller","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.063_bib21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40257-017-0310-0","article-title":"Diagnosis and treatment of rosacea fulminans: a comprehensive review","volume":"19","author":"Walsh","year":"2018","journal-title":"Am J Clin Dermatol"}],"updated-by":[{"DOI":"10.1016\/j.jaad.2020.01.031","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000}}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219308679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219308679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T21:57:36Z","timestamp":1668635856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219308679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0190962219308679"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.05.063","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jaad.2020.01.031","asserted-by":"object"}]},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized phase 3b\/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.05.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}